Alnylam price target raised to $450 from $342 at Scotiabank

Scotiabank raised the firm’s price target on Alnylam (ALNY) to $450 from $342 and keeps an Outperform rating on the shares. The company’s beat and raise underscores the “stellar” early launch momentum of Amvuttra in transthyretin amyloid cardiomyopathy, the analyst tells investors. The firm is increasing its price target to reflect updated expectations for Amvuttra’s growth trajectory.